EP3675728A1 - System and method for detecting and monitoring blast exposure using magnetic resonance spectroscopy (mrs) - Google Patents

System and method for detecting and monitoring blast exposure using magnetic resonance spectroscopy (mrs)

Info

Publication number
EP3675728A1
EP3675728A1 EP18851200.8A EP18851200A EP3675728A1 EP 3675728 A1 EP3675728 A1 EP 3675728A1 EP 18851200 A EP18851200 A EP 18851200A EP 3675728 A1 EP3675728 A1 EP 3675728A1
Authority
EP
European Patent Office
Prior art keywords
spectral data
subject
blast exposure
exposure
blast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18851200.8A
Other languages
German (de)
French (fr)
Other versions
EP3675728A4 (en
Inventor
Carolyn Mountford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Datchem
Original Assignee
Translational Res Institute Pty Ltd As Trustee For Translational Res Institute Trust
Translational Research Institute Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Translational Res Institute Pty Ltd As Trustee For Translational Res Institute Trust, Translational Research Institute Pty Ltd filed Critical Translational Res Institute Pty Ltd As Trustee For Translational Res Institute Trust
Publication of EP3675728A1 publication Critical patent/EP3675728A1/en
Publication of EP3675728A4 publication Critical patent/EP3675728A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0033—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room
    • A61B5/004—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part
    • A61B5/0042—Features or image-related aspects of imaging apparatus classified in A61B5/00, e.g. for MRI, optical tomography or impedance tomography apparatus; arrangements of imaging apparatus in a room adapted for image acquisition of a particular organ or body part for the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/16—Devices for psychotechnics; Testing reaction times ; Devices for evaluating the psychological state
    • A61B5/165—Evaluating the state of mind, e.g. depression, anxiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
    • A61B5/4064—Evaluating the brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/40—Detecting, measuring or recording for evaluating the nervous system
    • A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy
    • G01R33/485—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy based on chemical shift information [CSI] or spectroscopic imaging, e.g. to acquire the spatial distributions of metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/4625—Processing of acquired signals, e.g. elimination of phase errors, baseline fitting, chemometric analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/4633—Sequences for multi-dimensional NMR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/483—NMR imaging systems with selection of signals or spectra from particular regions of the volume, e.g. in vivo spectroscopy

Definitions

  • the present invention relates to a system and method for detecting and monitoring blast exposure using spectral data obtained using magnetic resonance spectroscopy.
  • Blast exposure is an increasingly common disorder affecting especially military personnel. Blast exposure soldiers have not shown detectable structural brain abnormalities on MRI images, SWI or FLAIR.
  • a system and method for diagnosing blast exposure using spectral data obtained using MRS.
  • the method comprises acquiring spectral data of a region of the brain of a subject, comparing the acquired spectral data with reference spectral data from normal subjects, and determining whether selected molecules in the obtained spectral data are different relative to the reference spectral data, to indicate that the subject has blast exposure.
  • the invention also provides a system for detecting blast exposure, and for monitoring the subject and progress of treatment.
  • the selected molecules may be one or more of NAA, Phenylalanine (PE), total fructose, a- fucose, fucosylated glycans III, and Myo-Inos + Cr.
  • the invention provides an effective and relatively objective in vivo method and system for detecting blast exposure, noninvasively, in a relatively fast and robust manner which also does not require any communication, counseling or therapy with the subject, thereby reducing the added stress and trauma attendant to the traditional ways of detecting blast exposure which remind subjects of the very disorder for which they are seeking treatment.
  • Figure 1 is a graph showing the % difference in detected concentration of certain neurochemicals of blast exposed soldiers and police with post traumatic stress disorder (PTSD) compared to civilian control subjects;
  • Figure 2 is a graph showing the % difference in detected concentrations of certain
  • Figure 3 is a block diagram of a system having a spectrometer, comparator and processor.
  • the present invention provides a method of detecting whether a subject has blast exposure comprising the steps of: acquiring spectral data of the region of a brain of a subject; comparing the acquired spectral data with reference spectral data obtained from normal subjects who have not been diagnosed with blast exposure; and determining whether selected molecules in the obtained spectral data differ in concentration relative to the reference spectral data to determine whether the subject has blast exposure based on the comparison.
  • the reference spectral data can be reference spectral data for subjects known to have blast exposure through other diagnosis, wherein the obtained spectral data is compared to the reference spectral data for known blast exposure subjects to see if a similarity exists.
  • the selected molecules may comprise at least one of the neurochemicals described above.
  • the acquired spectral data may be L-COSY 2D spectral data.
  • the method may further comprise repeating the steps of acquiring, comparing and determining while the subject is undergoing treatment for blast exposure, to determine the progress of treatment.
  • the invention also provides a system for detecting whether a subject has blast exposure comprising: a spectrometer acquiring spectral data of the region of a brain of a subject; a comparator for comparing the acquired spectral data with reference spectral data obtained from normal subjects who have not been diagnosed with blast exposure; and a processor for determining whether selected molecules in the obtained spectral data differ in concentration relative to the reference spectral data to determine whether the subject has blast exposure based on the comparison.
  • the system may in the alternative compare the obtained spectral data with referenced spectral data for subjects known to have blast exposure through other diagnosis, to see if a similarity exists.
  • the selected molecules may comprise at least one of the neurochemicals described above.
  • the acquired spectral data may be COSY 2D spectral data.
  • the system may comprise a memory for storing spectral data obtained from a subject from at least two different time periods, and wherein the processor compares two differently obtained spectral data to determine whether the subject is responding favorably to treatment.
  • Subjects who have been diagnosed with blast exposure using conventional psychological methods can be used to develop a reference database by having their brains scanned with an MR spectrometer separate or as part of a clinical MRI scanner of a magnetic resonance spectroscopy system.
  • the system can be a 3Tesla (3T) or higher MRI scanner using a 32 or 64 or greater channel head coil.
  • the pulse sequence used may be an L-COSY either ID or 2D. Further details on how to acquire such data may be found in Ramadan S. et al., In Vivo Two Dimensional MR Spectroscopy Compares the Biochemistry of the Human Brain and Glioblastoma, and Radiology, 2011. 259(2): p. 540-9 and Mountford, C, et al. Six fucose-alpha(l -2) sugars and alpha-fucose assigned in the human brain using in vivo two-dimensional MRS . NMR Biomed, 2015. 28(3): p. 291-6.
  • the spectral data from normal subjects will comprise a reference database in which certain molecules will have certain reference concentrations.
  • Subjects known to have blast exposure by conventional diagnostic methods have been found to have different concentration of certain molecules in their brain compared to normal or control subjects.
  • Figures 1 and 2 are graphs of concentrations of certain molecules of blast control subjects and how they differ from controls who are normal subjects.
  • a subject to be evaluated for possible blast exposure will undergo magnetic resonance spectroscopy of the brain to obtain the molecular concentration or ration of the molecules listed and possibly other telltale marker molecules.
  • a determination can be made on whether the suspected subject has blast exposure in an efficient and robust manner.
  • the comparison may also be made using a classifier method developed from a database.
  • Classifiers may be developed for automated diagnosis if desired, instead of or in addition to manual diagnosis.
  • Diffuse axonal injury (DAI) from blast exposure can arise from different types of measurable deregulation or damage.
  • 2D COSY provides specific DAI chemical changes providing a non-invasive and objective diagnosis more robust than conventional diagnosis methods.
  • the invention also includes treatment methods and monitoring to determine progress of subjects in treating the disorder.
  • Personalized treatment approaches can be employed, as the diagnosis method reveals the precise chemical imbalances that need correction. For example, if the diagnosis result indicates inflammation, the condition can be treated with anti-inflammatory medications or other treatment, and periodically monitored by testing the subject to determine the rate of recovery.
  • Targeted intervention will provide early response with benefit in long-term neuropsychological and neuropsychiatric outcomes.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Social Psychology (AREA)
  • Educational Technology (AREA)
  • Developmental Disabilities (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

A system and method identifies blast exposure by the use of magnetic resonance spectroscopy (MRS) to measure absolute and relative concentrations of metabolites in specific brain regions in the central nervous system or brain. The system and method can be used as a diagnostic tool for the assessment of blast exposure. These chemical changes in the brain of those people suffering from blast exposure are different from those suffering from head injury, chronic pain and other neurological conditions.

Description

SYSTEM AND METHOD FOR DETECTING AND MONITORING
BLAST EXPOSURE USING MAGNETIC RESONANCE SPECTROSCOPY (MRS)
BACKGROUND OF THE INVENTION
The present invention relates to a system and method for detecting and monitoring blast exposure using spectral data obtained using magnetic resonance spectroscopy.
Within this patent application are certain reference citations. These citations are incorporated herein by reference.
Blast exposure is an increasingly common disorder affecting especially military personnel. Blast exposure soldiers have not shown detectable structural brain abnormalities on MRI images, SWI or FLAIR.
SUMMARY OF THE INVENTION
It has been determined that the medical condition of blast exposure has neurological impact on a subject. Blast exposure has a distinctive neurological pattern, and the level of blast exposure is measureable using magnetic resonance spectroscopy (MRS).
In accordance with the present invention, a system and method are provided for diagnosing blast exposure using spectral data obtained using MRS. The method comprises acquiring spectral data of a region of the brain of a subject, comparing the acquired spectral data with reference spectral data from normal subjects, and determining whether selected molecules in the obtained spectral data are different relative to the reference spectral data, to indicate that the subject has blast exposure.
The invention also provides a system for detecting blast exposure, and for monitoring the subject and progress of treatment.
The selected molecules may be one or more of NAA, Phenylalanine (PE), total fructose, a- fucose, fucosylated glycans III, and Myo-Inos + Cr.
The invention provides an effective and relatively objective in vivo method and system for detecting blast exposure, noninvasively, in a relatively fast and robust manner which also does not require any communication, counseling or therapy with the subject, thereby reducing the added stress and trauma attendant to the traditional ways of detecting blast exposure which remind subjects of the very disorder for which they are seeking treatment.
Other advantages will be apparent from the following description and drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a graph showing the % difference in detected concentration of certain neurochemicals of blast exposed soldiers and police with post traumatic stress disorder (PTSD) compared to civilian control subjects;
Figure 2 is a graph showing the % difference in detected concentrations of certain
neurochemicals of breachers and artillery exposed subjects, and subjects with repetitive head injuries, compared to civilian control subjects; and
Figure 3 is a block diagram of a system having a spectrometer, comparator and processor.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
A preferred embodiment of the invention will be disclosed, but the invention will not be limited to this embodiment.
The present invention provides a method of detecting whether a subject has blast exposure comprising the steps of: acquiring spectral data of the region of a brain of a subject; comparing the acquired spectral data with reference spectral data obtained from normal subjects who have not been diagnosed with blast exposure; and determining whether selected molecules in the obtained spectral data differ in concentration relative to the reference spectral data to determine whether the subject has blast exposure based on the comparison. The reference spectral data can be reference spectral data for subjects known to have blast exposure through other diagnosis, wherein the obtained spectral data is compared to the reference spectral data for known blast exposure subjects to see if a similarity exists. The selected molecules may comprise at least one of the neurochemicals described above.. The acquired spectral data may be L-COSY 2D spectral data. The method may further comprise repeating the steps of acquiring, comparing and determining while the subject is undergoing treatment for blast exposure, to determine the progress of treatment.
The invention also provides a system for detecting whether a subject has blast exposure comprising: a spectrometer acquiring spectral data of the region of a brain of a subject; a comparator for comparing the acquired spectral data with reference spectral data obtained from normal subjects who have not been diagnosed with blast exposure; and a processor for determining whether selected molecules in the obtained spectral data differ in concentration relative to the reference spectral data to determine whether the subject has blast exposure based on the comparison. The system may in the alternative compare the obtained spectral data with referenced spectral data for subjects known to have blast exposure through other diagnosis, to see if a similarity exists.
The selected molecules may comprise at least one of the neurochemicals described above. The acquired spectral data may be COSY 2D spectral data. The system may comprise a memory for storing spectral data obtained from a subject from at least two different time periods, and wherein the processor compares two differently obtained spectral data to determine whether the subject is responding favorably to treatment.
Subjects who have been diagnosed with blast exposure using conventional psychological methods can be used to develop a reference database by having their brains scanned with an MR spectrometer separate or as part of a clinical MRI scanner of a magnetic resonance spectroscopy system. The system can be a 3Tesla (3T) or higher MRI scanner using a 32 or 64 or greater channel head coil. The pulse sequence used may be an L-COSY either ID or 2D. Further details on how to acquire such data may be found in Ramadan S. et al., In Vivo Two Dimensional MR Spectroscopy Compares the Biochemistry of the Human Brain and Glioblastoma, and Radiology, 2011. 259(2): p. 540-9 and Mountford, C, et al. Six fucose-alpha(l -2) sugars and alpha-fucose assigned in the human brain using in vivo two-dimensional MRS . NMR Biomed, 2015. 28(3): p. 291-6.
The spectral data from normal subjects will comprise a reference database in which certain molecules will have certain reference concentrations. Subjects known to have blast exposure by conventional diagnostic methods have been found to have different concentration of certain molecules in their brain compared to normal or control subjects.
Figures 1 and 2 are graphs of concentrations of certain molecules of blast control subjects and how they differ from controls who are normal subjects.
Blest b% os<- Bm&ch
These graphs show that the concentrations of selected neurochemicals of subjects having blast exposure differ significantly from those in normal or control subjects.
A subject to be evaluated for possible blast exposure will undergo magnetic resonance spectroscopy of the brain to obtain the molecular concentration or ration of the molecules listed and possibly other telltale marker molecules. By comparing the results with the reference molecule concentrations or ratios, a determination can be made on whether the suspected subject has blast exposure in an efficient and robust manner. The comparison may also be made using a classifier method developed from a database.
The changes may differ depending on the region of the brain being examined. Classifiers may be developed for automated diagnosis if desired, instead of or in addition to manual diagnosis.
Diffuse axonal injury (DAI) from blast exposure can arise from different types of measurable deregulation or damage.
2D COSY provides specific DAI chemical changes providing a non-invasive and objective diagnosis more robust than conventional diagnosis methods.
The invention also includes treatment methods and monitoring to determine progress of subjects in treating the disorder. Personalized treatment approaches can be employed, as the diagnosis method reveals the precise chemical imbalances that need correction. For example, if the diagnosis result indicates inflammation, the condition can be treated with anti-inflammatory medications or other treatment, and periodically monitored by testing the subject to determine the rate of recovery.
Targeted intervention will provide early response with benefit in long-term neuropsychological and neuropsychiatric outcomes.
Although one embodiment has been described, the invention is not limited to this embodiment and variations may occur to those skilled in the art. The scope is limited only by way of the claims.

Claims

1. A method of detecting whether a subject has blast exposure comprising the steps of: acquiring spectral data of the region of a brain of a subject;
comparing the acquired spectral data reference spectral data obtained from one of (i) normal subjects who have not been diagnosed with blast exposure, and (ii) subjects known to have blast exposure; and
determining whether selected molecules in the obtained spectral data differ or are similar in concentration relative to the reference spectral data to determine whether the subject has blast exposure based on the comparison.
2. The method of claim 1 , wherein the selected molecules comprise at least one of NAA, Phenylalanine (PE), total fructose, a-fucose, fucosylated glycans III, and Myo-Inos + Cr.
3. The method of claim 1, wherein the acquired spectral data is COSY 2D spectral data.
4. The method of claim 1 , further comprising repeating the steps of acquiring, comparing and determining while the subject is undergoing treatment for blast exposure, to determine the progress of treatment.
5. A system for detecting whether a subject has blast exposure comprising:
a spectrometer acquiring spectral data of the region of a brain of a subject;
a comparator for comparing the acquired spectral data with reference spectral data obtained from one of: (i) normal subjects who have not been diagnosed with blast exposure, and (ii) subjects known to have blast exposure; and
a processor for determining whether selected molecules in the obtained spectral data differ or are similar in concentration relative to the reference spectral data to determine whether the subject has PTSD based on the comparison.
6. The system of claim 5, wherein the selected molecules comprise at least one of NAA, Phenylalanine (PE), total fructose, a-fucose, fucosylated glycans III, and Myo-Inos + Cr.
7. The system of claim 5, wherein the acquired spectral data is COSY 2D spectral data.
8. The system of claim 5, further comprising a memory for storing spectral data obtained from a subject from at least two different time periods, and wherein the processor compares two differently obtained spectral data to determine whether the subject is responding favorably to treatment.
EP18851200.8A 2017-09-01 2018-08-31 System and method for detecting and monitoring blast exposure using magnetic resonance spectroscopy (mrs) Withdrawn EP3675728A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762553502P 2017-09-01 2017-09-01
PCT/IB2018/056683 WO2019043648A1 (en) 2017-09-01 2018-08-31 System and method for detecting and monitoring blast exposure using magnetic resonance spectroscopy (mrs)

Publications (2)

Publication Number Publication Date
EP3675728A1 true EP3675728A1 (en) 2020-07-08
EP3675728A4 EP3675728A4 (en) 2021-05-19

Family

ID=65525141

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18851200.8A Withdrawn EP3675728A4 (en) 2017-09-01 2018-08-31 System and method for detecting and monitoring blast exposure using magnetic resonance spectroscopy (mrs)

Country Status (3)

Country Link
EP (1) EP3675728A4 (en)
AU (1) AU2018326834A1 (en)
WO (1) WO2019043648A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3870031A4 (en) * 2018-10-24 2022-07-27 Datchem Pty Ltd Method and system for monitoring the progress of treatment of an individual having acute pain, chronic pain, acute stress disorder, blast exposure or ptsd using spectral data of the brain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006303026A1 (en) * 2005-10-18 2007-04-26 Psynova Neurotech Limited Methods and biomarkers for diagnosing and monitoring psychotic disorders such as schizophrenia
WO2009055818A1 (en) * 2007-10-25 2009-04-30 Research Foundation Of State University Of New York A spectral biomarker and algorithm for the identification and detection of neural stem and progenitor cells and their use in studying mammalian brains
EP2642919A4 (en) * 2010-11-26 2014-10-08 Brigham & Womens Hospital Method for assessing repetitive head injuries with tow-dimensional magnetic resonance spectorscopy
US20170209084A1 (en) * 2014-05-07 2017-07-27 University Of Utah Research Foundation Diagnosis of affective disorders using magnetic resonance spectroscopy neuroimaging
US20160377639A1 (en) * 2015-06-27 2016-12-29 William Beaumont Hospital Methods for detecting, diagnosing and treating traumatic brain injury
WO2017042635A1 (en) * 2015-09-10 2017-03-16 Translational Research Institute System and method for detecting and monitoring post traumatic stress disorder (ptsd) using magnetic resonance spectroscopy (mrs)

Also Published As

Publication number Publication date
AU2018326834A8 (en) 2022-02-17
WO2019043648A1 (en) 2019-03-07
EP3675728A4 (en) 2021-05-19
AU2018326834A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
Schneider et al. Diffusion tensor imaging in athletes sustaining repetitive head impacts: a systematic review of prospective studies
Meier et al. Longitudinal assessment of white matter abnormalities following sports‐related concussion
Murugavel et al. A longitudinal diffusion tensor imaging study assessing white matter fiber tracts after sports-related concussion
Metwalli et al. Utility of axial and radial diffusivity from diffusion tensor MRI as markers of neurodegeneration in amyotrophic lateral sclerosis
US7742800B2 (en) Methods and systems for detection and monitoring of neurodegenerative diseases using magnetic resonance spectroscopy
Tremblay et al. Multimodal assessment of primary motor cortex integrity following sport concussion in asymptomatic athletes
Abdel-Aziz et al. Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis
EP3346919A1 (en) System and method for detecting and monitoring post traumatic stress disorder (ptsd) using magnetic resonance spectroscopy (mrs)
Lista et al. Evolving evidence for the value of neuroimaging methods and biological markers in subjects categorized with subjective cognitive decline
US9612306B2 (en) Method for assessing repetitive head injuries with two-dimensional magnetic resonance spectroscopy
Toschi et al. Multishell diffusion imaging reveals sex-specific trajectories of early white matter degeneration in normal aging
AU2015231286B2 (en) Identifying different types of pain using magnetic resonance spectroscopy
Baglieri et al. Differences between conventional and non-conventional MRI techniques in Parkinson’s disease
Skouras et al. The effects of psychiatric history and age on self-regulation of the default mode network
Dennis et al. Magnetic resonance spectroscopy of fiber tracts in children with traumatic brain injury: A combined MRS–Diffusion MRI study
Long et al. A case-control proton magnetic resonance spectroscopy study confirms cerebellar dysfunction in benign adult familial myoclonic epilepsy
Schuff et al. Reanalysis of multislice 1H MRSI in amyotrophic lateral sclerosis
Race et al. Psychosocial impairment following mild blast-induced traumatic brain injury in rats
Shahim et al. Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI
WO2019043648A1 (en) System and method for detecting and monitoring blast exposure using magnetic resonance spectroscopy (mrs)
Chen et al. GABA-induced motor improvement following acute cerebral infarction
RU2675160C1 (en) Diagnostic technique for cognitive disorders at early stage in patients with dyscirculatory encephalopathy
Miyata et al. Facial nerve atrophy in patients with amyotrophic lateral sclerosis: evaluation with fast imaging employing steady‐state acquisition (FIESTA)
US11346909B2 (en) Systems architecture for analysis of spectroscopy and fMRI data using multiple integrated classifiers
Xue et al. Chronic pontine strokes: diffusion tensor imaging of corticospinal tract indicates the prognosis in terms of motor outcome

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200211

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210416

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/055 20060101AFI20210412BHEP

Ipc: G01R 33/46 20060101ALI20210412BHEP

Ipc: A61B 5/145 20060101ALI20210412BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DATCHEM

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211116